Primordial Genetics today announced the first closing of its Series A-2 financing round, including a group of 5 private investors.
The company will use the capital it has raised to support additional R&D activities to develop superior microbial strains for production of high-value proteins including human therapeutic proteins and industrial enzymes.
Related Articles
-
-
-
-
Primordial Genetics and Denovium Collaborate to Impact the Diagnosis, Prevention & Treatment of Human Diseases
The Research is Supported by the National Human Genome Research Institute of the National Institutes of Health Primordial Genetics,...
-
Primordial Genetics receives Notice of Allowance from USPTO covering Function Generator combinatorial genetics technology.
Primordial Genetics is pleased to announce that the United States Patent and Trademark Office has issued a Notice of...
-
-
Primordial Genetics signs R&D Agreement for pharmaceutical manufacturing.
Following the launch of an R&D project for improvement of an enzyme used for manufacturing high-value pharmaceuticals in November...
-
Go Beyond Investing conducts due diligence on Primordial Genetics
Go Beyond Investing (https://go-beyond.biz/) is a FinTech company transforming angel investing into a new scalable asset class for small...
0 Comments